(Bloomberg) -- India has proposed zero tariffs on steel, auto components and pharmaceuticals on a reciprocal basis up to a certain quantity of imports in its trade negotiations with the US, people familiar with the matter said. Most Read from Bloomberg The Battle Over the Fate of Detroit’s Renaissance Center NYC Real Estate Industry Asks Judge to Block New Broker Fee Law NJ Transit Strike Would Be ‘Disaster’ for Region, Sherrill Says Iceland Plans for a More Volcanic Future Vail to Borrow Muni Debt to Ease Ski Resort Town Housing Crunch Beyond this threshold, imported industrial goods would attract the regular level of duties, the people said, asking not to be identified as the discussions are private. The offer was made by Indian trade officials visiting Washington late last month to expedite negotiations on a bilateral trade deal expected by fall this year, the people said. The two nations are prioritizing certain sectors to strike an early trade deal before the end of the 90-day pause on US President Donald Trump’s tit-for-tat tariffs, the people said. Amid a contraction in the US economy, Trump suggested Sunday that some trade deals could be sealed as soon as this week, offering the prospect of relief for trading partners seeking to avoid higher US import duties. Asian economies, including South Korea, Japan and India are among the nations leading the race for reaching interim deals with his administration. An email to India’s Ministry of Commerce and Industry was not immediately answered. Washington has also asked India to resolve its concerns around Quality Control Orders, which it considers a non-tariff trade barrier for its exports, the people said. The mandatory quality standards, which lay down benchmarks that both local and foreign manufacturers must meet before selling their goods in India, have been criticized for being non-transparent and unfair. India is willing to reconsider its existing QCOs in sectors such as medical devices and chemicals, and has offered to sign a mutual recognition agreement with the US under which both nations will accept each other’s regulatory standards and practices. It’s unclear if these proposals will form part of the final deal. From just 14 QCOs before 2014, the number has gone up to more than 140 since 2017, a report showed. Most Read from Bloomberg Businessweek US Border Towns Are Being Ravaged by Canada’s Furious Boycott Made-in-USA Wheelbarrows Promoted by Trump Are Now Made in China 100 Moments You Might Have Missed From Trump’s First 100 Days How an Israeli Hostage Negotiator Outsmarts Ransomware Hackers Inside the Dizzying Chaos of Running a Freight Business Under Trump ©2025 Bloomberg L.P. View Comments
India Offers Zero-for-Zero Tariffs on Auto Parts, Steel From US
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...